Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of epidermal growth factor ointment for anti-EGFR agent related skin disorders
jRCTs041200113Phase 1Completed
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epidermal growth factor in colorectal cancer (CRC), colon cancer, rectal cancer and 1 more. Primary endpoints: Incidence of dose limiting toxicity and Rate of improvement in skin rash. Started Mar 2021; status: completed.
02
Drugs
epidermal growth factor
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancercutaneous rash
Beyond the preview
Go deeper on jRCTs041200113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200113.